News
In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...
Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...
Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone ...
Misinterpretation of MRI findings by clinicians focused on earlier intervention is leading to increased rates of ...
5d
MarketBeat on MSNEli Lilly : A Breakout Biotech Powerhouse With Room to RunEli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...
5d
Dealbreaker on MSNEli Lilly Pays $1 Billion For Non-Opioid Pain Med MakerEli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...
Denmark's Novo Nordisk faces mounting pressure — from cheap copycats to US tariff threats — putting its weight-loss empire at ...
Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...
Big Pharma is using dark money to fund groups that sound like patient advocacy organizations but represent the industry.
Global pharmaceutical giant Eli Lilly & Co. is considering a $5.9 billion plant in northeast Houston, a potential economic jolt that could accelerate the city’s ambitions to become a national ...
Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA for the sleep apnoea pill.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results